Bio-Rad Laboratories, Inc. (BIO) Net Profit Margin: 6.52%
Is Bio-Rad Laboratories, Inc.’s net profit margin high or low?
Bio-Rad Laboratories, Inc.'s net profit margin of 6.52% is 61% below its 5-year average of 16.61%, around the middle of its 5-year range (-129.45%–149.83%).
The net profit margin for Bio-Rad Laboratories, Inc. (BIO) is 6.52% as of Wednesday, June 10, 2026. It is above its 12-month average by 130.73% (-21.22%).
BIO Net Profit Margin Chart
BIO Average Net Profit Margin Chart
BIO Current vs Average Net Profit Margin Chart
BIO Net Profit Margin Metrics
NET PROFIT MARGIN
6.52%
NET PROFIT MARGIN AVG TTM
-21.22%
NET PROFIT MARGIN AVG 3Y
-48.94%
NET PROFIT MARGIN AVG 5Y
16.61%
NET PROFIT MARGIN AVG 10Y
18.52%
NET PROFIT MARGIN AVG 15Y
14.87%
NET PROFIT MARGIN AVG 20Y
12.97%
CURRENT VS TTM AVG
+130.73%
CURRENT VS 3Y AVG
+113.32%
CURRENT VS 5Y AVG
-60.74%
CURRENT VS 10Y AVG
-64.80%
CURRENT VS 15Y AVG
-56.15%
CURRENT VS 20Y AVG
-49.75%
BIO Competitors' Net Profit Margin
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bio-Rad Laboratories, Inc. (BIO) | $7.89B | 6.52% | -21.22% | -48.94% | 16.61% |
| Charles River Laboratories International, Inc. (CRL) | $9.06B | -4.59% | -1.67% | 5.09% | 7.31% |
| Hims & Hers Health, Inc. (HIMS) | $6.42B | -0.56% | 7.00% | -0.29% | -8.82% |
| Baxter International Inc. (BAX) | $10.49B | -9.70% | -7.30% | -3.29% | 1.14% |
| Align Technology, Inc. (ALGN) | $12.56B | 10.50% | 10.36% | 10.48% | 22.21% |
| Hologic, Inc. (HOLX) | $16.97B | 13.18% | 16.70% | 17.87% | 22.37% |
| Moderna, Inc. (MRNA) | $18.40B | -143.55% | -128.24% | -70.25% | -50.87% |
| BioNTech SE (BNTX) | $21.81B | -44.73% | -31.89% | 3.77% | 12.08% |
| Mettler-Toledo International Inc. (MTD) | $22.85B | 21.40% | 21.94% | 21.74% | 21.20% |
| Waters Corporation (WAT) | $23.83B | 11.91% | 20.93% | 21.85% | 22.39% |
Margin Comparison
Operating Margin
9.3%
Net Profit Margin
6.5%
Bio-Rad Laboratories, Inc. Net Profit Margin Formula & Definition
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Bio-Rad Laboratories, Inc. Net Profit Margin FAQ
- What is the net profit margin for Bio-Rad Laboratories, Inc. (BIO)?
- The net profit margin for BIO stock is 6.52%.
- Is Bio-Rad Laboratories, Inc.'s net profit margin high or low?
- Bio-Rad Laboratories, Inc.'s net profit margin of 6.52% is 61% below its 5-year average of 16.61%, around the middle of its 5-year range (-129.45%–149.83%).
- What is the TTM average net profit margin for Bio-Rad Laboratories, Inc. (BIO)?
- The TTM average net profit margin for BIO stock is -21.22%.
- What is the 3Y average net profit margin for Bio-Rad Laboratories, Inc. (BIO)?
- The 3Y average net profit margin for BIO stock is -48.94%.
- What is the 5Y average net profit margin for Bio-Rad Laboratories, Inc. (BIO)?
- The 5Y average net profit margin for BIO stock is 16.61%.
- What is the 10Y average net profit margin for Bio-Rad Laboratories, Inc. (BIO)?
- The 10Y average net profit margin for BIO stock is 18.52%.
- What is the 15Y average net profit margin for Bio-Rad Laboratories, Inc. (BIO)?
- The 15Y average net profit margin for BIO stock is 14.87%.
- What is the 20Y average net profit margin for Bio-Rad Laboratories, Inc. (BIO)?
- The 20Y average net profit margin for BIO stock is 12.97%.
Bio-Rad Laboratories, Inc. Net Profit Margin History
| DATE | NET PROFIT MARGIN |
|---|---|
| 2025-12-31 | 29.42% |
| 2024-12-31 | -71.86% |
| 2023-12-31 | -23.86% |
| 2022-12-31 | -129.45% |
| 2021-12-31 | 145.57% |
| 2020-12-31 | 149.83% |
| 2019-12-31 | 76.08% |
| 2018-12-31 | 15.76% |
| 2017-12-31 | 5.31% |
| 2016-12-31 | 1.36% |
| 2015-12-31 | 5.60% |
| 2014-12-31 | 4.08% |
| 2013-12-31 | 3.65% |
| 2012-12-31 | 8.18% |
| 2011-12-31 | 8.60% |
| 2010-12-31 | 9.63% |
| 2009-12-31 | 8.11% |
| 2008-12-31 | 5.07% |
| 2007-12-31 | 6.36% |
| 2006-12-31 | 8.11% |
| 2005-12-31 | 6.91% |
| 2004-12-31 | 6.26% |
| 2003-12-31 | 7.59% |
| 2002-12-31 | 7.60% |
| 2001-12-31 | 5.40% |
| 2000-12-31 | 4.28% |
| 1999-12-31 | 2.13% |
| 1998-12-31 | 5.50% |
| 1997-12-31 | 3.84% |
| 1996-12-31 | 6.26% |
Related Metrics
About Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Norman D. Schwartz